Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 46,052

Document Document Title
WO/2014/041106
The invention relates to compounds of formula (I), wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen; X1 is -N= or ...  
WO/2014/041111
Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.  
WO/2014/041179
A method of treating or preventing peripheral neuropathy in a subject determined to be in need thereof comprising: topically administering to the subject an anti-peripheral neuropathic compound acting as GFRα3 type receptor agonist.  
WO/2014/040228
The present invention relates to the stabilised amorphous form of the compound of formula (I), to a process for its preparation and also to pharmaceutical compositions or medicaments containing it.  
WO/2014/043110
The invention provides powerful methods and compositions for designing, selecting, fine-tuning and optimizing polymer nanogel and other supramolecular assemblies for various properties including, for example, particle size, density and m...  
WO/2014/043685
Disclosed are compositions, such as liquid and solid nutritional compositions, that contain beta-hydroxy-beta-methylbutyric acid and optionally at least one protein, carbohydrate, fat, or a combination of protein, carbohydrate, and fat. ...  
WO/2014/043330
Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods ...  
WO/2014/042238
The invention provides a novel sulfonamide compound useful as a drug having a TRPM8-blocking effect. Specifically, the invention provides a sulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I...  
WO/2014/042176
Provided are an industrially useful method for producing a fused-heterocyclic derivative or salt thereof which is useful as a preventive agent, therapeutic agent, reproductive adjustment agent, contraceptive, ovulation-inducing agent, or...  
WO/2014/041175
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q1, Q2 have the following meanings: X is C-R3 or...  
WO/2014/043368
Disclosed are methods for enhancing learning and/or memory, enhancing memory acquisition, memory retention and recall by inducing a higher long-term potentiation in hippocampal neuronal synapsis in individuals. The methods include admini...  
WO/2014/043068
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and...  
WO/2014/039501
Bolaamphiphilic compounds are provided according to formula (I): where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into anim...  
WO/2014/037532
The present invention describes methods of treating dementia comprising administering an effective daily dose of N-(2-(6-fluoro-lH-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropo xy)benzylamine to improve or augment the effect of an acetylcho...  
WO/2014/039074
The present invention generally relates to therapeutic compositions for the treatment of mammalian disease and related methods. It more specifically relates to compositions comprising peptides for the treatment of inflammation and method...  
WO/2014/036595
The present disclosure relates to quinoline compounds of formula I, compositions comprising them and methods and uses for the treatment of central nervous system disorders, such as mood disorders (eg. depression), anxiety disorders, and ...  
WO/2014/039411
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may ...  
WO/2014/037412
The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising a...  
WO/2014/039908
Provided are methods and compositions for inducing cells of the inner ear (for example, cochlear and utricular hair cells) to reenter to cell cycle and to proliferate. More particularly, the invention relates to the use of agents that in...  
WO/2014/038878
The present invention relates to a composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk as an active ingredient, and the composition has an outstanding pharmacological eff...  
WO/2014/038623
Provided is a therapeutic agent for diseases associated with central nervous system (CNS) and/or peripheral nervous system (PNS) cholinergicity, diseases associated with smooth muscle contraction, endocrine diseases, diseases associated ...  
WO/2014/039504
Bolaamphiphilic compounds are provided according to formula I where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering biologically active drug...  
WO/2014/037881
The present invention pertains to the field of genomics and nanotechnology, specifically to the in vivo gene expression technologies and their application in gene therapy. It consists of the performance of the NTS-polyplex nanocomplex, w...  
WO/2014/037832
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enatitiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount...  
WO/2014/037834
The compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof are disclosed. The pharmaceutical compositions comprising an effective amo...  
WO/2014/039434
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising t...  
WO/2014/040076
The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-α.  
WO/2014/038878
The present invention relates to a composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk as an active ingredient, and the composition has an outstanding pharmacological eff...  
WO/2014/039138
The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acy...  
WO/2014/035860
The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β- secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in...  
WO/2014/034756
The present invention relates to the provision of a pharmaceutical composition for use in the treatment of status epilepticus or a method for treating status epilepticus. The present invention provides a pharmaceutical composition for us...  
WO/2014/034719
A compound represented by general formula (1), a salt of the compound, or a solvate of the compound or the salt, which can inhibit TLR3, 7 and/or 9 and has an excellent prophylactic and/or therapeutic effect on autoimmune diseases, infla...  
WO/2014/034898
The main purpose of the invention is to provide a novel pyridine derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include a pyridine derivative represented by general formula [1], and a pharmaceutically...  
WO/2014/032187
The invention provides compounds of Formula (I) for inhibiting gh cosidases, prodrugs of the compounds, and pharmaceutical compositions comprising the compounds or prodrugs of the compounds. The invention also provides method of treating...  
WO/2014/033530
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein G, R2-R5, and (a) are defined as set forth in the specification. The invention is also directed to use...  
WO/2014/035707
The present invention provides compounds and composition comprising analogs of deprenyl and their use in the inhibition of nuclear GAPDH-Siahl binding and the activation of p300 and MEF2. Also provided herein are methods of prevention an...  
WO/2014/032732
The invention relates to novel halogenated benzoxazines, to methods for the production thereof, use thereof for the diagnosis of diseases and to the use thereof for producing medicaments for the diagnosis of diseases, preferably dementia...  
WO/2014/032801
The invention relates to pyrrole carboxamides bearing a fluoromethyl- moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or...  
WO/2014/036182
Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.  
WO/2014/034890
A hypnotic/sedative agent comprising methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2- a][1,4]benzodiazepin-4-yl]propanoate or a salt thereof is administered to a vein of a patient by a two-step administration method as dis...  
WO/2014/032185
The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and d...  
WO/2014/032184
The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and d...  
WO/2014/032188
The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and d...  
WO/2014/034939
The purpose of the present invention is to provide a rivastigmine-containing adhesive skin patch which has excellent skin permeability of rivastigmine contained therein and has excellent adhesion performance. The present invention provid...  
WO/2014/036379  
WO/2014/033074
The present disclosure relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same.  
WO/2014/034929
The present invention addresses the problem of providing a hydromorphone hydrochloride- or oxycodone hydrochloride hydrate-containing orally-administered sustained-release pharmaceutical composition, which exhibits a reliable main pharma...  
WO/2014/035355
The present invention is related to pharmaceutical compositions comprising idebenone and memantine in combination which are used in the treatment of cerebral arteriosclerosis, symptoms following stroke and cerebral hemorrhage, age-associ...  
WO/2014/036427
Described herein are compositions and methods for treating or imaging Alzheimer's disease (AD). The compositions comprise a biotin moiety and a siRNA moiety, without the need for a targeting agent such as an antibody, avidin, or streptav...  
WO/2014/031792
Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepti...  

Matches 401 - 450 out of 46,052